Halle/Westfalen, Germany, July 18, 2013 – Baxter’s BioPharma Solutions business, a leading global contract manufacturing organiza - tion, announced that it has launched a new packaging line at its Halle/Westfalen, Germany, facility. The new line allows Baxter to meet the advanced packaging requirements of its pharmaceutical clients worldwide, as well as accommodating emerging packaging needs including serialization and enhanced safety measures. The line became operational after a thorough, 18-month planning and implementation process led by Baxter and in conjunction with vendors, suppliers and clients.
“As an organization that collaborates with a diverse group of pharmaceutical companies, Baxter’s BioPharma Solutions business is committed to continually improving and modernizing our state-of-the-art capabilities in both production and packaging,” said Dr. Burkhard Wichert, vice president of manufacturing for Baxter’s BioPharma Solutions business. “This new line in the Halle facility not only greatly increases our capacity for high-quality, complex packaging, it supports our mission to help save and sustain lives by supplying customers and patients with the products they need.”
The new line offers Baxter’s contract manufacturing clients access to capabilities including printing of variable data; booklet packaging; 100% OCR/OCV of variable data; and control weighing for completeness. These compliment Baxter’s already advanced ll- nish capabilities that helped BioPharma Solutions be named “Best Contract Manufacturing Organization” three years in a row at the Vaccine Industry Excellence Awards, among other industry awards.
hile the line has only been operational a short time, one Baxter client has already lauded the “real bene t for the packaging of our products” and noted that “such initiative from Baxter demonstrates their ongoing commitment to continually enhance equipment and facilities to help ensure best possible performance for our bene t.” (As a matter of policy, and in order to adhere to its strict con dentiality requirements, Baxter does not disclose the names or other identifying information of BioPharma Solutions’ contract manufacturing clients.) The launch of this new packaging line follows on the announce - ment in February 2013 of a further expansion at Baxter’s Halle facility to support BioPharma Solutions’ cytotoxic contract manufacturing services. That expansion enhanced Halle's capacity to provide a complete range of resources to support early-phase drug manufacturing through commercial scale-up, product launch and lifecycle manage - ment.
“Baxter’s BioPharma Solutions business remains committed to meeting clients’ and patients’ needs,” said Dr. Wichert. "Whether through the expansion announced earlier this year or this new packag - ing line, we continue to invest in the Halle/Westfalen, Germany, facility to support this commitment day-in, day-out and worldwide."
Help employers find you! Check out all the jobs and post your resume
